Why the study?
Does chronic propranolol treatment prevent the development of cardiomyopathy in transgenic mice with cardiac Gsα overexpression?
Does chronic propranolol treatment prevent the development of cardiomyopathy in transgenic mice with cardiac Gsα overexpression?
Chronic beta-adrenergic receptor blockade with propranolol prevents the development of cardiomyopathy, preserves cardiac function, and abolishes premature mortality in a transgenic mouse model of chronic sympathetic overstimulation.
Answers are grounded in this paper and cite their sources.
Supports beta-blockade in sympathetic overstimulation models; leaves open human translation pending prospective trials.
Transgenic (TG) mice with cardiac G(salpha) overexpression exhibit enhanced inotropic and chronotropic responses to sympathetic stimulation, but develop cardiomyopathy with age. We tested the hypothesis that cardiomyopathy in TG mice with G(salpha) overexpression could be averted with chronic beta-adrenergic receptor (beta-AR) blockade. TG mice and age-matched wild-type littermates were treated with the beta-AR blocker propranolol for 6-7 months, starting at a time when the cardiomyopathy was developing but was not yet severe enough to induce significant cardiac depression (9.5 months of age), and ending at a time when cardiac depression and cardiomyopathy would have been clearly manifest (16 months of age). Propranolol treatment, which can induce cardiac depression in the normal heart, actually prevented cardiac dilation and the depressed left ventricular function characteristic of older TG mice, and abolished premature mortality. Propranolol also prevented the increase in myocyte cross-sectional area and myocardial fibrosis. Myocyte apoptosis, already apparent in 9-month-old TG mice, was actually eliminated by chronic propranolol. This study indicates that chronic sympathetic stimulation over an extended period is deleterious and results in cardiomyopathy. Conversely, beta-AR blockade is salutary in this situation and can prevent the development of cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Asai et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: